Analysis of baseline interstitial lung abnormality on the risk of checkpoint inhibitor-related pneumonitis and survival in advanced non-small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors
Pre-existing ILA is an independent risk factor that is strongly associated with CIP, and significantly correlated with worse PFS and OS in advanced NSCLC patients after first-line immunotherapy.
Authors
- Wanjun Lu
- Wolfgang M. Brueckl (ORCID: https://orcid.org/0000-0002-7039-0791)
- Marko Jakopović (ORCID: https://orcid.org/0000-0002-4815-7512)
- Tangfeng Lv (ORCID: https://orcid.org/0000-0001-7224-8468)
- Qiuxia Wu (ORCID: https://orcid.org/0000-0003-3043-5841)
- Yanjun Du (ORCID: https://orcid.org/0000-0002-0762-9077)
- Yuxin Jiang
- Li Yu (ORCID: https://orcid.org/0000-0001-8513-1883)
- Jun Yao (ORCID: https://orcid.org/0000-0002-4506-3369)
- Dong Wang (ORCID: https://orcid.org/0000-0001-6545-3578)
- Ping Zhan
- Fumihiro Yamaguchi
- Shuo Liang (ORCID: https://orcid.org/0009-0003-7996-4776)
- Qin Wang (ORCID: https://orcid.org/0009-0004-3954-7879)
- Fang Zhang (ORCID: https://orcid.org/0000-0002-9944-7448)
Institutions
- Nanjing University of Chinese Medicine (CN)
- University Hospital Centre Zagreb (HR)
- University of Zagreb (HR)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Paracelsus Medizinische Privatuniversität (DE)
- Yancheng Third People's Hospital (CN)
- SHOWA Medical University Fujigaoka Hospital (JP)
- Southeast University (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21037/tlcr-2025-150
- Citations
- 5
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 7.59